• Vaccine Name: Brucella abortus strain 19 salt-extractable protein subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009105
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: Mus musculus (BALB/c mice)
• Antigen: salt-extractable periplasmic proteins (BCSP70, BCSP100, and subfractions BCSP100-A, BCSP100-B, BCSP100-C, BCSP100-D) | salt-extractable protein (CSP)
• Adjuvant: mophosphoryl lipid A (MPL) from Salmonella typhimurium Re mutant strain | Freund's complete adjuvant
• Preparation: Vaccines were prepared from BCSP70 and BCSP100 protein fractions and four subfractions (BCSP100-A through BCSP100-D) purified by anion-exchange HPLC; some formulations included monophosphoryl lipid A (MPL) as an immune response modifier. (Pugh et al, 1996)
  CSP formulated with Freund's complete adjuvant (Confer et al, 1987)
• Description: The study evaluated immune and protective responses induced by vaccination with six salt-extractable periplasmic protein fractions from Brucella abortus strain 19. Efficacy: Vaccines prepared from BCSP70 and BCSP100 were moderately protective and immunogenic; subfractions BCSP100-A through BCSP100-D were not protective without MPL; MPL enhanced protection or was neutral with BCSP70, BCSP100, BCSP100-C, and BCSP100-D; some subfractions increased bacterial survival and splenomegaly. Immune response: MPL modulated immunoglobulin G responses induced by BCSP70, BCSP100, and BCSP100-B vaccines; overall, certain protein fractions may act as virulence or survival factors in infection. (Pugh et al, 1996)
  Beef heifers were vaccinated on Day 0 with salt-extractable protein (CSP) from Brucella abortus Strain 19 in Freund's complete adjuvant; a booster was given six weeks later with either homologous or heterologous vaccine. Efficacy: No significant protection observed; 60 to 83% of vaccinated heifers aborted and 70-83% were culture positive after challenge, similar to controls Immune response: Vaccination stimulated marked antibody responses and increased cell-mediated immune response measured by lymphocyte blast transformation; antibody responses increased rapidly after challenge and were higher in heifers that aborted; LBT responses were higher in vaccinates but not significantly different from controls (Confer et al, 1987)

Cattle Response

• Vaccination Protocol: Beef heifers were vaccinated on Day 0 with salt-extractable protein (CSP) from Brucella abortus Strain 19 in Freund's complete adjuvant; a booster was given six weeks later with either homologous or heterologous vaccine. (Confer et al, 1987)
• Immune Response: Vaccination stimulated marked antibody responses and increased cell-mediated immune response measured by lymphocyte blast transformation; antibody responses increased rapidly after challenge and were higher in heifers that aborted; LBT responses were higher in vaccinates but not significantly different from controls (Confer et al, 1987)
• Challenge Protocol: Vaccination of beef heifers followed by serologic tests, enzyme-linked immunosorbent assay, fluorometric immunoassay, lymphocyte blast transformation assay, and intraconjunctival challenge with Brucella abortus strain 2308. (Confer et al, 1987)
• Efficacy: No significant protection observed; 60 to 83% of vaccinated heifers aborted and 70-83% were culture positive after challenge, similar to controls (Confer et al, 1987)
• Description: Vaccination of beef heifers followed by serologic tests, enzyme-linked immunosorbent assay, fluorometric immunoassay, lymphocyte blast transformation assay, and intraconjunctival challenge with Brucella abortus strain 2308 (Confer et al, 1987)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were vaccinated with the protein fractions and later challenged with Brucella abortus 2308; protection was assessed by measuring colony-forming units (CFU) in spleens and spleen size; serologic responses were measured by enzyme-linked immunosorbent assay (ELISA). (Pugh et al, 1996)
• Immune Response: MPL modulated immunoglobulin G responses induced by BCSP70, BCSP100, and BCSP100-B vaccines; overall, certain protein fractions may act as virulence or survival factors in infection. (Pugh et al, 1996)
• Challenge Protocol: BALB/c mice were vaccinated with the protein fractions and later challenged with Brucella abortus 2308; protection was assessed by measuring colony-forming units (CFU) in spleens and spleen size; serologic responses were measured by enzyme-linked immunosorbent assay (ELISA). (Pugh et al, 1996)
• Efficacy: Vaccines prepared from BCSP70 and BCSP100 were moderately protective and immunogenic; subfractions BCSP100-A through BCSP100-D were not protective without MPL; MPL enhanced protection or was neutral with BCSP70, BCSP100, BCSP100-C, and BCSP100-D; some subfractions increased bacterial survival and splenomegaly. (Pugh et al, 1996)
• Description: BALB/c mice were vaccinated with the protein fractions and later challenged with Brucella abortus 2308; protection was assessed by measuring colony-forming units (CFU) in spleens and spleen size; serologic responses were measured by enzyme-linked immunosorbent assay (ELISA). (Pugh et al, 1996)